Most Watched by Traders: Neuralstem, Inc., Caladrius Biosciences (NASDAQ:CLBS)

Onvia Inc. (NASDAQ:ONVI) shares fell -1.51% in last trading session and ended the day at $3.92. ONVI Gross Margin is 85.50% and its has a return on assets of -5.30%. Onvia Inc. (NASDAQ:ONVI) quarterly performance is -3.45%.

Onvia, Inc. (NASDAQ: ONVI), announced its financial results for the third quarter ended September 30, 2015. Subscription revenue for the quarter ended September 30, 2015 grew 6% over the same period in 2014. The growth in subscription revenue reflects a sustained growth in ACV over the past year. Total revenue for the quarter ended September 30, 2015 was $5.9 million, up 3% compared to the same period last year. In addition to subscription revenue, total revenue includes content license and report revenue.

Bazaarvoice, Inc. (NASDAQ:BV) ended the last trading day at $4.51. Company weekly volatility is calculated as 4.13% and price to cash ratio as 3.52. Bazaarvoice, Inc. (NASDAQ:BV) showed a weekly performance of -0.88%.

On October 20, 2015, the Board of Directors Bazaarvoice, Inc. (NASDAQ:BV), appointed Steven H. Berkowitz as a member of the Board, effective immediately, and designated Mr. Berkowitz as a Class II director to stand for election at the Company’s 2016 annual meeting of stockholders. The Board appointed Mr. Berkowitz as a member of the Board’s Nominating and Governance Committee, effective upon his appointment to the Board.

On 09 November, Summer Infant, Inc. (NASDAQ:SUMR) shares advanced 4.66% and was closed at $1.96. SUMR EPS growth in last 5 year was -15.20%. Summer Infant, Inc. (NASDAQ:SUMR) year to date (YTD) performance is -39.88%.

Summer Infant, Inc. (NASDAQ:SUMR), announced financial results for the third quarter and nine months ended October 3, 2015. Net sales for the three months ended October 3, 2015 were $50.2 million compared with $51.0 million for the three months ended September 30, 2014. Excluding $1.5 million and $2.7 million of sales related to non-core business in licensed, private label, and furniture sales during the third quarter of fiscal 2015 and 2014, respectively, as well as $0.8 million in unfavorable foreign exchange effect on a constant currency basis in fiscal 2015, core branded sales increased by 2.5%.

Neuralstem, Inc. (NASDAQ:CUR) shares advanced 4.31% in last trading session and ended the day at $1.21. And its has a return on assets of -70.40%. Neuralstem, Inc. (NASDAQ:CUR) quarterly performance is -9.02%.

Neuralstem, Inc. (Nasdaq: CUR) reported its financial results and business update for the three and nine months ended September 30, 2015. Cash, cash equivalents and short-term investments on hand was approximately $18.1 millionat September 30, 2015, compared to approximately $27.5 millionat December 31, 2014. The decrease was primarily due to our cash used in operations partially offset by our raising approximately $6.0 million, net through the issuance of our common stock from warrant exercises and from the sale of our common stock.

Caladrius Biosciences, Inc. (NASDAQ:CLBS) caters to the Healthcare space. Its weekly performance is -1.50%. On the last day of trading company shares ended up at $1.31. Caladrius Biosciences, Inc. (NASDAQ:CLBS) distance from 50-day simple moving average (SMA50) is 5.24%.

Caladrius Biosciences, Inc. (NASDAQ:CLBS) announces that the Company presented two posters including new clinical and analytical data at the Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting, which took place from November 4-8 in Baltimore, Maryland. The data, drawn from ongoing analysis and follow-up from a completed Phase 2 study, further support the technology being explored in a currently enrolling Phase 3 clinical trial to investigate Caladrius’ lead product candidate, CLBS20, for the treatment of metastatic melanoma.